We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Ivax has launched the first generic version of Pfizer’s profitable epilepsy drug, Neurontin — a decision that could result in stiff financial penalties if a court later rules Ivax infringed on Pfizer’s patents.